Albireo to Participate in Jefferies London Healthcare Conference

Rhea-AI Summary

Albireo Pharma (Nasdaq: ALBO) announced its participation in the Jefferies London Healthcare Conference from November 15-17, 2022. CFO Simon Harford will present on November 15 at 10:20 AM GMT. The event will be available for on-demand viewing on the Albireo Investors page.

Albireo focuses on developing novel bile acid modulators for treating pediatric and adult liver diseases. Its lead product, Bylvay, has FDA approval for treating pruritus associated with progressive familial intrahepatic cholestasis (PFIC) and is undergoing clinical trials for other rare liver diseases.

News Market Reaction – ALBO

-15.35%

-15.35% Session move

In the trading session that priced this news, ALBO declined 15.35%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Jefferies London Healthcare Conference in London, UK, from November 15-17, 2022. Simon Harford, Chief Financial Officer of Albireo, will be presenting on November 15, 2022, at 10:20 AM GMT.

A replay of the webcast will be available on-demand on the Albireo Investors page: ir.albireopharma.com.

About Albireo   
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase 3 trial in Alagille syndrome (ALGS), an ongoing Phase 3 study in biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com. 

Media Contacts:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com

Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578

FAQ

When is Albireo Pharma presenting at the Jefferies London Healthcare Conference?

Albireo Pharma will present on November 15, 2022, at 10:20 AM GMT.

What products does Albireo Pharma develop for liver diseases?

Albireo Pharma develops novel bile acid modulators, including Bylvay, approved for treating pruritus in PFIC.

Where can I watch the Albireo Pharma conference presentation?

The conference presentation will be available on-demand on Albireo's Investors page.

What is the significance of Bylvay in liver disease treatment?

Bylvay is the first drug approved for treating pruritus in all types of PFIC.

What clinical trials is Albireo Pharma currently conducting?

Albireo is conducting Phase 3 trials for Alagille syndrome and biliary atresia, along with studies for other rare liver diseases.